Review
Rev Diabet Stud,
2010,
7(2):132-143 |
DOI 10.1900/RDS.2010.7.132 |
Mesenchymal Stem Cells as Feeder Cells for Pancreatic Islet Transplants
Valeria Sordi, Lorenzo Piemonti
San Raffaele Diabetes Research Institute (HSR-DRI), Division of Immunology, Transplantation and Infectious Disease, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
Address correspondence to: Valeria Sordi, e-mail: sordi.valeria@hsr.it
Manuscript submitted July 20, 2010; resubmitted August 7, 2010; accepted August 9, 2010.
Keywords: stem cell, feeder, islet, co-transplantation, revascularization, bone marrow, immunomodulation
Abstract
Allogeneic islet transplantation serves as a source of insulin-secreting beta-cells for the maintenance of normal glucose levels and treatment of diabetes. However, limited availability of islets, high rates of islet graft failure, and the need for life-long non-specific immunosuppressive therapy are major obstacles to the widespread application of this therapeutic approach. To overcome these problems, pancreatic islet transplantation was recently suggested as a potential target of the "therapeutic plasticity" of adult stem cells. In fact, new results suggest that stem/precursor cells, and mesenchymal stem cells in particular, co-transplanted with islets can promote tissue engraftment and beta-cell survival via bystander mechanisms, mainly exerted by creating a milieu of cytoprotective and immunomodulatory molecules. This evidence consistently challenges the limited view that stem/precursor cells work exclusively through beta-cell replacement in diabetes therapy. It proposes that stem cells also act as "feeder" cells for islets, and supporter of graft protection, tissue revascularization, and immune acceptance. This article reviews the experience of using stem cell co-transplantation as strategy to improve islet transplantation. It highlights that comprehension of the mechanisms involved will help to identify new molecular targets and promote development of new pharmacological strategies to treat type 1 and type 2 diabetes patients.
Fulltext:
HTML
, PDF
(937KB)
This article has been cited by other articles:
|
IL-12 involvement in myogenic differentiation of C2C12 in vitro
Romanazzo S, Forte G, Morishimace K, Taniguchi A
Biomaterial Sci 2015. 2015(3):469-479
|
|
|
Bone marrow- and cord blood-derived stem cell transplantation for diabetes therapy
Cantarelli E, Pellegrini S, Citro A, Sordi V, Piemonti L
CellR4 2015. 3(1):e1408
|
|
|
Manipulation of cell sorting within mesenchymal stromal cell-islet cell multicellular spheroids
Hoffecker IT, Iwata H
Tissue Eng Part A 2014. 20(11-12):1643-1653
|
|
|
Design of bioartificial pancreas with functional micro/nano-based encapsulation of islets
Kepsutlu B, Nazli C, Bal T, Kizilel S
Curr Pharm Biotechnol 2014. 15(7):590-608
|
|
|
Selected cytokines in patients with pancreatic cancer: a preliminary report
Błogowski W, Deskur A, Budkowska M, Sałata D, Madej-Michniewicz A, Dabkowski K, Dolegowska B, Starzynska T
Plos One 2014. 9(5):e97613
|
|
|
In vivo bioluminescence imaging of transplanted mesenchymal stem cells as a potential source for pancreatic regeneration
Lee S, Youn H, Chung T, Hwang do W, Oh SW, Kang KW, Chung JK, Lee DS
Mol Imaging 2014. 2014:13
|
|
|
The impact of oxidative stress on islet transplantation and monitoring the graft survival by non-invasive imaging
Ramkumar KM, Sekar TV, Bhakkiyalakshmi E, Foygel K, Rajaguru P, Berger F, Paulmurugan R
Curr Med Chem 2013. 20(9):1127-1146
|
|
|
Contribution of murine bone marrow mesenchymal stem cells to pancreas regeneration after partial pancreatectomy in mice
Han F, Wang CY, Yang L, Zhan SD, Zhang M, Tian K
Cell Biol Int 2012. 36(9):823-831
|
|
|
A Step-up Approach for Cell Therapy in Stroke: Translational Hurdles of Bone Marrow-Derived Stem Cells
Glover LE, Tajiri N, Weinbren NL, Ishikawa H, Shinozuka K, Kaneko Y, Watterson DM, Borlongan CV
Transl Stroke Res 2012. 3(1):90-98
|
|
|
Genetically engineered islets and alternative sources of insulin-producing cells for treating autoimmune diabetes: quo vadis?
Chou FC, Huang SH, Sytwu HK
Int J Endocrinol 2012. 2012:296485
|
|
|
The great migration of bone marrow-derived stem cells toward the ischemic brain: therapeutic implications for stroke and other neurological disorders
Borlongan CV, Glover LE, Tajiri N, Kaneko Y, Freeman TB
Prog Neurobiol 2011. 95(2):213-228
|
|
|
New hope for type 2 diabetics: targeting insulin resistance through the immune modulation of stem cells
Zhao Y, Jiang Z, Guo C
Autoimmun Rev 2011. 11(2):137-142
|
|
|
A step-up approach for cell therapy in stroke: translational hurdles of bone marrow-derived stem cells
Glover LE, Tajiri N, Weinbren NL, Ishikawa H, Shinozuka K, Kaneko Y, Watterson DM, Borlongan CV
Transl Stroke Res 2011. In press
|
|
|
Current status of immunomodulatory and cellular therapies in preclinical and clinical islet transplantation
Chhabra P, Brayman KL
J Transplant 2011. 2011:637692
|
|
|
Beta-cell generation: can rodent studies be translated to humans?
Carlotti F, Zaldumbide A, Ellenbroek JH, Spijker HS, Hoeben RC, de Koning EJ
J Transplant 2011. 2011:892453
|
|
|
Human placenta-derived mesenchymal stem cells and islet-like cell clusters generated from these cells as a novel source for stem cell therapy in diabetes
Kadam S, Muthyala S, Nair P, Bhonde R
Rev Diabet Stud 2010. 7(2):168-182
|
|
|